BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33350967)

  • 1. Management of cytokine release syndrome after chimeric antigen T-cell therapy for paediatric relapsed/refractory acute lymphoblastic leukaemia: a case report.
    Cheng FWT; Li BS; Lam GKS; Hon KL; Joynt G; Li CK
    Hong Kong Med J; 2020 Dec; 26(6):532-534. PubMed ID: 33350967
    [No Abstract]   [Full Text] [Related]  

  • 2. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
    Benjamin R; Graham C; Yallop D; Jozwik A; Mirci-Danicar OC; Lucchini G; Pinner D; Jain N; Kantarjian H; Boissel N; Maus MV; Frigault MJ; Baruchel A; Mohty M; Gianella-Borradori A; Binlich F; Balandraud S; Vitry F; Thomas E; Philippe A; Fouliard S; Dupouy S; Marchiq I; Almena-Carrasco M; Ferry N; Arnould S; Konto C; Veys P; Qasim W;
    Lancet; 2020 Dec; 396(10266):1885-1894. PubMed ID: 33308471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
    Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
    Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.
    Aldoss I; Khaled SK; Budde E; Stein AS
    Curr Oncol Rep; 2019 Jan; 21(1):4. PubMed ID: 30666425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
    Luan C; Zhou J; Wang H; Ma X; Long Z; Cheng X; Chen X; Huang Z; Zhang D; Xia R; Ge J
    Front Immunol; 2021; 12():707191. PubMed ID: 34349766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
    Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
    J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
    Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
    Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy.
    Ragoonanan D; Tambaro FP; Khazal SJ; Tewari P; Petropoulos D; Champlin R; Mahadeo KM
    Pediatr Blood Cancer; 2021 May; 68(5):e28839. PubMed ID: 33258192
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
    Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
    Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
    Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
    Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Supportive Care for Acute Lymphoblastic Leukemia.
    Cook J; Litzow M
    Curr Hematol Malig Rep; 2020 Aug; 15(4):276-293. PubMed ID: 32607955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report].
    Shchekina AE; Galstyan GM; Gavrilina OA; Arapova NM; Bronyakina SI; Kotova ES; Troitskaya VV; Parovichnikova EN; Maschan MA; Savchenko VG
    Ter Arkh; 2021 Jul; 93(7):811-817. PubMed ID: 36286733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Three cases of hemodiafiltration for the treatment of CAR-T related grade 3 - 4 cytokine release syndrome after ineffective treatment with IL-6 receptor inhibitors].
    Chen SY; Chen WH; Wan XC; Du X; Luo CR; Li XQ; Zhang XH
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):494-498. PubMed ID: 35968593
    [No Abstract]   [Full Text] [Related]  

  • 16. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
    Frey NV
    Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Heng G; Jia J; Li S; Fu G; Wang M; Qin D; Li Y; Pei L; Tian X; Zhang J; Wu Y; Xiang S; Wan J; Zhu W; Zhang P; Zhang Q; Peng X; Wang L; Wang P; Wei Z; Zhang Y; Wang G; Chen X; Zhang C; Sun Y; Zhao W; Fan Y; Yang Z; Chen J; Qian C
    Clin Cancer Res; 2020 Apr; 26(7):1606-1615. PubMed ID: 31732519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity. Be Aware and Prepared.
    Azoulay E; Shimabukuro-Vornhagen A; Darmon M; von Bergwelt-Baildon M
    Am J Respir Crit Care Med; 2019 Jul; 200(1):20-23. PubMed ID: 30676776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management Principles Associated With Cytokine Release Syndrome.
    Baer B; Dudley CV; Simons RM
    Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of cytokine release syndrome related to CAR-T cell therapy.
    Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
    Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.